Literature DB >> 11000236

Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells.

A Krithivas1, D B Young, G Liao, D Greene, S D Hayward.   

Abstract

The human herpesvirus 8 (HHV-8) latency-associated nuclear antigen (LANA) is expressed in all latently HHV-8 infected cells and in HHV-8-associated tumors, including primary effusion lymphoma (PEL). To better understand the contribution of LANA to tumorigenesis and to the PEL phenotype, we performed a yeast two-hybrid screen which identified the corepressor protein SAP30 as a LANA binding protein. SAP30 is a constituent of a large multicomponent complex that brings histone deacetylases to the promoter. Glutathione S-transferase affinity assays confirmed interaction between LANA and SAP30 and also demonstrated interactions between LANA and two other members of the corepressor complex, mSin3A and CIR. The corepressors bound to the amino-terminal 340-amino-acid domain of LANA. In transient expression assays, this same domain of LANA mediated repression when targeted to a 5xGal4tk-CAT reporter as a GAL4-LANA fusion. PEL cells have the unusual feature that they are frequently dually infected with both HHV-8 and Epstein-Barr virus (EBV). We found that EBV EBNA-1 expression is downregulated in PEL cells at both the RNA and protein levels. In transient expression assays, LANA repressed activated expression from the EBV Qp and Cp latency promoters. Reduction of endogenous Qp activity could also be demonstrated in EBV-infected Rael cells transfected with a LANA expression plasmid. In contrast to the effect of LANA on EBV latency promoters, LANA activated expression from its own promoter. The data indicate that LANA can mediate transcriptional repression through recruitment of an mSin3 corepressor complex and further that LANA-mediated repression is likely to contribute to the low level of EBV latency gene expression seen in dually infected PEL cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000236      PMCID: PMC112396          DOI: 10.1128/jvi.74.20.9637-9645.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line.

Authors:  S J Talbot; R A Weiss; P Kellam; C Boshoff
Journal:  Virology       Date:  1999-04-25       Impact factor: 3.616

2.  Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.

Authors:  J J Hsieh; T Henkel; P Salmon; E Robey; M G Peterson; S D Hayward
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders.

Authors:  J J Oudejans; M Jiwa; A J van den Brule; F A Grässer; A Horstman; W Vos; P M Kluin; P van der Valk; J M Walboomers; C J Meijer
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

4.  Primary body cavity-based AIDS-related lymphomas. Evolution of a new disease entity.

Authors:  E S Jaffe
Journal:  Am J Clin Pathol       Date:  1996-02       Impact factor: 2.493

5.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

6.  Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.

Authors:  P S Moore; S J Gao; G Dominguez; E Cesarman; O Lungu; D M Knowles; R Garber; P E Pellett; D J McGeoch; Y Chang
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

8.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.

Authors:  E Cesarman; P S Moore; P H Rao; G Inghirami; D M Knowles; Y Chang
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

9.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  115 in total

1.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.

Authors:  Jianhong Hu; Alexander C Garber; Rolf Renne
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes.

Authors:  Anita Krithivas; Masahiro Fujimuro; Magdalena Weidner; David B Young; S Diane Hayward
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32.

Authors:  Kersten T Hall; Mathew S Giles; Michael A Calderwood; Delyth J Goodwin; David A Matthews; Adrian Whitehouse
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Chromosome binding site of latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus is essential for persistent episome maintenance and is functionally replaced by histone H1.

Authors:  Hirohiko Shinohara; Masaya Fukushi; Masaya Higuchi; Masayasu Oie; Osamu Hoshi; Tatsuo Ushiki; Jun-Ichi Hayashi; Masahiro Fujii
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells.

Authors:  Takahiro Watanabe; Makoto Sugaya; April M Atkins; Elisabeth A Aquilino; Aparche Yang; Debra L Borris; John Brady; Andrew Blauvelt
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 6.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

7.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

8.  Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome.

Authors:  Chunghun Lim; Hekwang Sohn; Daeyoup Lee; Yousang Gwack; Joonho Choe
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Human Herpesvirus 8: Biology and Role in the Pathogenesis of Kaposi's Sarcoma and Other AIDS-related Malignancies.

Authors:  Abel Viejo-Borbolla; Matthias Ottinger; Thomas F. Schulz
Journal:  Curr Infect Dis Rep       Date:  2003-04       Impact factor: 3.725

10.  The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency.

Authors:  Nathaniel J Moorman; David O Willer; Samuel H Speck
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.